4.6 Article

Emulating the MERINO randomised control trial using data from an observational cohort and trial of rapid diagnostic (BSI-FOO)

期刊

PLOS ONE
卷 17, 期 5, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0268807

关键词

-

资金

  1. National Institute for Health Research (NIHR) Programme Grants for Applied Research [RP-PG-0707-10043]
  2. British Heart Foundation
  3. NIHR Bristol Biomedical Research Unit for Cardiovascular Disease and North Bristol Charitable Funds
  4. National Institutes of Health Research (NIHR) [RP-PG-0707-10043] Funding Source: National Institutes of Health Research (NIHR)

向作者/读者索取更多资源

The aim of this study was to emulate the MERINO trial comparing the efficacy of piperacillin-tazobactam and meropenem for the treatment of bloodstream infection caused by ceftriaxone-nonsusceptible E coli or Klebsiella spp. The results showed that the mortality rate in the emulated trial population was higher than that in the MERINO trial, and the effect size was smaller after adjustment for propensity score.
Objective The aim of this study was to emulate the MERINO trial of piperacillin-tazobactam vs meropenem for the definitive treatment of bloodstream infection (BSI) caused by ceftriaxone-nonsusceptible E coli or Klebsiella spp. Methods Data from an observational study of BSI and a randomised controlled trial of a rapid diagnostic in BSI were used to emulate the MERINO trial. The primary outcome of the emulated trial was 28-day mortality after blood culture. Outcomes were compared using logistic regression adjusted for propensity score for emulated intervention. Results Of the 6,371 observational study and RCT participants, 1,968 had a bloodstream infection with E. coli or Klebsiella spp. of which 121 met the eligibility criteria. In the emulated trial, a total of 14/82 patients (17.1%) allocated to piperacillin-tazobactam met the primary outcome compared with 6/39 (15.4%) in the meropenem group (unadjusted odds ratio 1.13 (95% CI 0.40 to 3.21)). After adjustment for propensity score, the odds ratio increased to 1.31 (95% CI 0.40 to 4.26). This difference is in the same direction but of a smaller magnitudethan observed in the MERINO trial, where 30-day mortality was met by 23/187 patients (12.3%) in the piperacillin-tazobactam and 7/191 (3.7%) in the meropenem group (unadjusted odds ratio of 3.69 (95% CI 1.48 to 10.41)). Conclusions The mortality rate in an emulated trial population was more than double the mortality rate in the MERINO trial. The methodology used attempts to address the concern that previous results could be explained by biases such as selection bias and uncontrolled confounding and provides information on how a trial such as the MERINO trial may have performed in the NHS.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据